TABLE 2.
Best overall response to first‐line treatment.
| All | Synaptophysin | Chromogranin A | NCAM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |||||||||
| ICI‐c | c | ICI‐c | c | ICI‐c | c | ICI‐c | c | ICI‐c | c | ICI‐c | c | |||
| N | 30 | 197 | 26 | 153 | 4 | 38 | 22 | 100 | 8 | 84 | 28 | 182 | 2 | 10 |
| Response, % | ||||||||||||||
| CR | 0 (0%) | 1 (0.5%) | 0 (0%) | 1 (0.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.6%) | 0 (0%) | 0 (0%) |
| PR | 25 (83.3%) | 160 (81.2%) | 22 (84.6%) | 126 (82.4%) | 3 (75.0%) | 29 (76.3%) | 18 (81.8%) | 82 (82.0%) | 7 (87.5%) | 68 (81.0%) | 24 (85.7%) | 148 (81.3%) | 1 (50.0%) | 8 (80.0%) |
| SD | 0 (0%) | 16 (8.1%) | 0 (0%) | 13 (8.5%) | 0 (0%) | 2 (5.3%) | 0 (0%) | 7 (7.0%) | 0 (0%) | 7 (8.3%) | 0 (0%) | 16 (8.8%) | 0 (0%) | 0 (0%) |
| PD | 3 (10.0%) | 10 (5.1%) | 1 (3.8%) | 8 (5.2%) | 1 (25.0%) | 2 (5.3%) | 2 (9.1%) | 6 (6.0%) | 1 (12.5%) | 4 (4.8%) | 2 (7.1%) | 10 (5.5%) | 1 (50.0%) | 0 (0%) |
| NE | 1 (3.3%) | 10 (5.1%) | 2 (7.7%) | 5 (3.3%) | 0 (0%) | 5 (13.1%) | 1 (4.5%) | 4 (4.0%) | 0 (0%) | 5 (6.0%) | 1 (3.6%) | 7 (3.8%) | 0 (0%) | 2 (20.0%) |
| N‐CR/N‐PD | 1 (3.3%) | 0 (0%) | 1 (3.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.5%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.6%) | 0 (0%) | 0 (0%) | 0 (0%) |
| ORR, % | 83.3% | 81.7% | 84.6% | 83.1% | 75.0% | 76.3% | 81.8% | 83.0% | 87.5% | 81.0% | 85.7% | 81.9% | 50.0% | 80.0% |
| p‐value | 0.106 | 0.166 | 0.457 | 0.313 | 0.669 | 0.149 | 0.182 | |||||||
Abbreviations: c, chemotherapy; CR, complete response; ICI‐c, immune checkpoint inhibitor plus chemotherapy; NCAM, neural cell adhesion molecule; N‐CR/N‐PD, not complete response/not progressive disease; NE, neuroendocrine; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.